Please visit answersincme.com/NPK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma (MM) answers common questions about incorporating novel cereblon E3 ligase modulators (CELMoDs) in early-relapse therapy for patients with MM. Upon completion of this activity, participants should be better able to: Identify the rationale for incorporating novel CELMoDs in early-relapse therapy in patients with MM; Discuss the clinical impact of the latest data for emerging novel CELMoDs in the early-relapse setting for patients with MM; and Describe potential considerations for integrating novel CELMoDs in the treatment landscape of MM as they become available.